Navigation Links
Laureate Pharma Appoints Daniel E. Leone as Vice President of Business Development
Date:7/28/2009

PRINCETON, N.J., July 28 /PRNewswire/ -- Laureate Pharma, Inc., a full-service biopharmaceutical development and protein production company, today announced the appointment of Daniel E. Leone as Vice President of Business Development. Mr. Leone will be responsible for Laureate's worldwide business development activities, including sales and marketing. He will be supporting the company's contract development, manufacturing, and bioprocessing business.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080131/NETH020LOGO )

"We are pleased to welcome Dan to Laureate's Leadership Team," said Robert J. Broeze, Ph.D., President and CEO of Laureate. "Dan is a seasoned executive with more than 20 years of experience in business development and he brings an impressive background that includes broad international business development and management experience in contract manufacturing, pharmaceuticals and specialty chemicals. His capabilities include strong leadership, and strategic and organizational skills that have produced positive results in early stage and mature businesses."

Most recently Dan served as Executive Director of Contract Manufacturing at Ben Venue Laboratories where he was responsible for Sales, Marketing and New Business Development for its parenteral contract manufacturing services business. Prior to Ben Venue, Dan was the Vice President of Business Operations at Boehringer Ingelheim Chemicals where he was responsible for Sales, Marketing, New Business Development and Supply Chain Management for its active pharmaceutical ingredients business. Prior to BI, Dan held positions of increasing responsibility at Hoechst Corporation. While at Hoechst Dan served as their Global Director, Ventures in Hoechst's Research and Technology Division where he was responsible for general management of several early stage businesses. Dan earned an MBA from Duke University and Masters and Bachelors degrees in Chemical Engineering from Manhattan College.

About Laureate Pharma

Laureate Pharma is a full-service biopharmaceutical development and protein production company located in Princeton, New Jersey. Laureate Pharma offers superior bioprocessing services that accelerate new products from development through production. Laureate provides a wide range of specialized services from process design and development to full-scale cGMP production, purification, aseptic filling, testing, validation, analytical services, and regulatory support. Laureate is focused on two active segments of the biopharmaceutical industry: monoclonal antibodies and recombinant protein products. For more information, contact us at info@laureatepharma.com or visit www.laureatepharma.com.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Robert Broeze

https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=84360


'/>"/>
SOURCE Laureate Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Nobel Laureate Lee Hartwell to Retire as President and Director of Fred Hutchinson Cancer Research Center in 2010
2. US Oncology Named 2009 Laureate by IDG Computerworld Honors Program
3. Nobel Laureates to Speak at Keystone Symposia RNA Silencing Conference
4. Laureate Pharma Honored as Emerging Life Sciences Company of the Year
5. Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.
6. Laureate Announces Manufacturing Agreement with Tolerx
7. Laureate Pharma to Add More Manufacturing Capacity
8. ARUP Laboratories ARUP Consult(R) Recognized as a Computerworld Honors Program Laureate
9. Laureate Pharma Announces Manufacturing Agreement With Alopexx Pharmaceuticals, LLC
10. Laureate Pharma Reports Record Growth for 2007
11. Laureate Pharma Appoints Gary Swan as Vice President of Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)...  The Prostate Cancer Foundation (PCF) is pleased to announce 24 ... for prostate cancer. Members of the Class of 2016 were selected from a ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... 2016   EpiBiome , a precision microbiome engineering ... debt financing from Silicon Valley Bank (SVB). The financing ... advance its drug development efforts, as well as purchase ... "SVB has been an incredible strategic partner to us ... bank would provide," said Dr. Aeron Tynes Hammack ...
(Date:6/23/2016)... ... , ... STACS DNA Inc., the sample tracking software company, today announced that ... joined STACS DNA as a Field Application Specialist. , “I am thrilled that ... of STACS DNA. “In further expanding our capacity as a scientific integrator, Hays brings ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
Breaking Biology Technology:
(Date:6/20/2016)... Securus Technologies, a leading provider of ... safety, investigation, corrections and monitoring announced that after ... secured the final acceptance by all three (3) ... Systems (MAS) installed. Furthermore, Securus will have contracts ... by October, 2016. MAS distinguishes between legitimate wireless ...
(Date:6/9/2016)... attendance control systems is proud to announce the introduction of fingerprint attendance control software, ... employees are actually signing in, and to even control the opening of doors. ... ... ... Photo - http://photos.prnewswire.com/prnh/20160609/377487 ...
(Date:6/3/2016)... 3, 2016 Das ... Nepal hat ein 44 ... geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, ... Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte ... Januar teilgenommen, aber Decatur wurde als konformste ...
Breaking Biology News(10 mins):